JPMorgan Bullish on Eli Lilly as Weight-Loss Dominance Expands
JPMorgan Chase analyst Chris Schott raised Eli Lilly's price target to $1,150 from $1,050, maintaining an Overweight rating after meetings with management reinforced confidence in the company's trajectory. The pharmaceutical giant's market capitalization recently eclipsed $1 trillion, fueled by a 54% year-over-year revenue surge to $17.60 billion in Q3.
Key to the bullish thesis is Lilly's Medicare/Medicaid agreement for obesity drugs, a strategic coup that solidifies its lead in the weight-loss therapeutics race. The upcoming launch of an oral weight-loss medication—positioned as more patient-friendly than injectables—could further accelerate growth.
Schott's upgrade reflects Lilly's dual advantage: near-term policy tailwinds and a pipeline primed to extend its dominance in metabolic treatments. The stock's rally mirrors Wall Street's appetite for healthcare innovators with clear pricing power and scalable therapies.
